Acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6225311A · kind A · utility
28Cited by
9References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2000 |
| Grant date | May 1, 2001 |
| Priority date | — |
| Expiry date | Jan 27, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula: ##STR1## are useful in treating disease conditions mediated by TNF-.alpha., such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.